Prospects for the future in the management of carcinoma of the breast: The biological fall out from clinical trials
Open Access
- 1 February 1984
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 49 (2), 117-122
- https://doi.org/10.1038/bjc.1984.22
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factorNature, 1980
- The contribution of recent nsabp clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findingsCancer, 1980
- Treatment and survival on advanced breast cancer.BMJ, 1978
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978
- Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replicationCancer, 1977
- OVARIAN FUNCTION IN PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST CANCERThe Lancet, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Macrophage production by the bone marrow of tumor-bearing mice.1972
- SIGNIFICANCE OF REGIONAL LYMPH NODE METASTASES IN BREAST CARCINOMA1965